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Abstract The ethnic variation in the GGN and CAG
microsatellites of the androgen receptor (AR) gene
suggests their role in the substantial racial difference in
prostate cancer risk. Hence, we performed a case-
control study to assess whether GGN repeats inde-
pendently or in combination with CAG repeats were
associated with prostate cancer risk in South Indian
men. The repeat lengths of the AR gene determined by
Gene scan analysis, revealed that men with GGN re-
peats £21 had no significant risk compared to those
with >21 repeats (OR 0.91 at 95% CI-0.52–1.58).
However, when CAG repeats of our earlier study was
combined with the GGN repeat data, the cases
exhibited significantly higher frequency of the haplo-
types CAG £19/GGN £21 (OR-5.2 at 95% CI-2.17–
12.48, P < 0.001) and CAG £19/GGN > 21(OR-6.9 at
95%CI-2.85–17.01, P < 0.001) compared to the con-
trols. No significant association was observed between
GGN repeats and prostate-specific antigen levels and
the age at diagnosis. Although a trend of short GGN
repeats length in high-grade was observed, it was not
significant (P = 0.09). Overall, our data reveals that
specific GGN/CAG haplotypes (CAG £19/GGN £21
and CAG £19/GGN > 21) of AR gene increase the
risk of prostate cancer and thus could serve as sus-
ceptibility marker for prostate cancer in South Indian
men.
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Introduction
The incidence of clinical prostate cancer differs sub-
stantially between ethnic groups, where African
Americans exhibit a 10-to 40-fold higher incidence
than Asians (Gronberg 2003). Despite an expanding
body of epidemiological data, the etiology of prostate
cancer remains poorly understood. However, evi-
dences support the involvement of both genetic and
environmental factors, which might also attribute to
the ethnic differences in incidence rates.
The growth and development of the prostate gland,
together with the maintenance of its physiological
integrity, are dependent on the circulating androgens and
intact intracellular steroid signaling pathways (Cunha
et al. 1987). The effects of androgens are mediated
through the androgen receptor (AR), a ligand-activated
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nuclear transcription factor encoded by AR gene,
located on the X chromosome (Xq11–12). The AR gene
comprised of 8 exons, spanning more than 90 kb of the
genomic DNA, encodes the AR protein with four func-
tional domains including an amino-terminal transcrip-
tion activation domain (TAD), the DNA binding
domain (DBD), a hinge region and the carboxyl-termi-
nal ligand-binding domain (LBD) (Janne et al.1993).
Androgens, particularly dihydrotestosterone, bind to the
AR with high affinity and stimulate the transcription of a
cascade of androgen-responsive genes. In addition to
stimulating the expression of genes associated with the
differentiated phenotype of the prostate, such as pros-
tate-specific antigen (PSA), it has been reported that AR
may regulate genes involved in cell-cycle control, e.g.,
cyclin dependent kinases like CDK2, CDK4 and p16
(Lu et al. 1997). Thus, the AR transactivation plays an
important role in the normal growth and function of the
prostate gland. Exon 1 of the gene contains the poly-
morphic CAG and GGN repeat motifs, which are
approximately 1.1 kb apart encoding polyglutamine and
a polyglycine tract, respectively (Edwards et al. 1992).
GGN repeat is complex in nature and composed of
(GGT) 3(GGG) 1(GGT) 2(GGC) n (Platz et al. 1998).
The number of CAG repeats ranges from 8 to 35 with
an average of 20–23 repeats and the GGN tract varies
from about 10–35 repeats. In vitro investigations suggest
that CAG repeat length correlate inversely with AR
transactivation (Chamberlain et al. 1994). The longer
CAG repeat length found to be associated with male
infertility (Patrizio et al. 2001), while the short CAG
repeat length of the AR has been reported to predispose
to prostate cancer (Coetzee et al. 1994; Mishra et al.
2005; Krishnaswamy et al. 2006). However, the effect of
the variation in the length of the GGN tract on AR
activity is unclear. Results from earlier studies on tran-
sient transfection of reporter constructs have shown that
deletion of the GGN tract resulted in either no alteration
or increased or decreased AR transcriptional activity
(Jenster et al. 1994, Gao et al. 1996). Jenster et al. (1994)
found that complete deletion of the (GGC) n sequence
had no substantial effect on AR activity, whereas Gao
et al. (1996) found that the same mutation resulted in a
diminished capacity (30% reduction) to activate the
luciferase gene.
Epidemiological investigations on the association
between the number of GGN repeats and prostate
cancer risk have produced inconsistent results. Because
of the ethnic variation in CAG and GGN repeat
lengths of the AR gene and the role of AR in andro-
genic activity, it has been suggested that the polymor-
phism may help explain part of the large ethnic
difference in prostate cancer risk.
In India, a significant association has been identified
between short CAG repeats and prostate cancer risk in
North Indian men (Mishra et al. 2005), as well as our
earlier study on the South Indian men (Krishnaswamy
et al. 2006). This raised curiosity to determine the role
of GGN repeat polymorphisms and its linkage with
CAG repeats in prostate cancer risk in South Indian
men. Therefore, we have analyzed the relation be-
tween AR-GGN microsatellite and prostate cancer risk
and investigated whether this relation varies with tu-
mor grade, PSA levels and age at diagnosis. Moreover,
we assessed whether specific combination of CAG and
GGN microsatellite alleles shows significant associa-
tion with prostate cancer risk. In addition, we also
tested for a possible linkage between the repeats




The present case-control study comprised of 86 histo-
logically confirmed prostate cancer patients and 119
male control subjects from the southern part of India.
The controls comprised of 79 healthy, age-matched and
unrelated individuals with normal serum PSA levels
(£4 ng/ml), digital rectal examination showing no
abnormality and with no history of cancer and 40
subjects with benign prostatic hyperplasia (BPH). Both
patients and control individuals were from the same
ethnic background. Relevant clinical and pathological
data were collected for all the patients. The age of
prostate cancer patients ranged from 44 to 98 years
with mean age of 67.5 years, in BPH patients it was 55–
77 years with mean of 65.5 years and in normal healthy
controls the age ranged between 50 and 81 years with
mean of 66.5 years. Pathological grading of the tumors
by Gleason scores (GS) were obtained and the patients
were stratified as low grade if their Gleason scores
were less than 7 and high grade if their Gleason scores
were greater than or equal to 7. The Gleason score was
less than 7 in 47 patients and greater than or equal to 7
in 39 patients. The study was approved by the Institu-
tional Medical and Ethics Committee. Blood samples
were collected from both the patients and controls with
an informed written consent.
Genotyping of GGN repeat polymorphism
Genomic DNA was isolated from blood leucocytes by
standard phenol/chloroform method (Sambrook et al.
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1989). Exon 1 of AR gene was genotyped using the
primers flanking the GGN repeat motif: 5¢FAM-
CCGCTTCCTCATCCTGGCACAC 3¢ (forward pri-
mer) and 5¢ GCCGCCAGGGTACCACACATC 3¢
(reverse primer). Each PCR was carried out in a 10 ll
reaction mixture containing 20 ng DNA, 1 ll of
10 · PCR buffer, 5 pM of each primer, 200 lM dNTPs
(deoxynucleotide triphosphates), 0.4 ll of 100%
DMSO, 0.6 ll of 100% Glycerol and 0.5 U of Amp-
liTaq Gold (Perkin–Elmer). PCR conditions consisted
of initial denaturation of 96C for 12 min, followed by
30 cycles each consisting of 1 min 30 s at 96C, 1 min at
60C and 3 min at 72C followed by a final extension at
72C for 5 min. For GeneScan analysis, 3.0 ll of the
PCR product was mixed with 0.2 ll of LIZ500TM and
6.8 ll of formamide. Upon, denaturation for 5 min at
95C and cooling for 5 min on ice, the samples were
run on ABI 3730 DNA analyzer (Applied Biosystems,
USA). The raw data were further analyzed using
GeneMapper software to determine the number of
repeats. The PCR and the genotyping were repeated
for all the samples to confirm the number of repeats.
Genotyping of CAG repeat polymorphism was
performed by PCR followed by GeneScan analysis on
ABI3730 Genetic Analyzer as described earlier
(Krishnaswamy et al. 2006)
Statistical analysis
The descriptive measures like mean, median and
standard deviation of various characteristics such as
age, PSA levels, tumor grade, CAG and GGN repeats
of the subjects were calculated. Comparison of the
mean GGN repeat length among the cases and controls
were carried out using unpaired t test. The mean GGN
repeat was used to categorize the subjects into two
groups and the relative risk associated with GGN re-
peats was determined by calculating odds ratio (OR).
The difference in proportion of specific CAG and
GGN alleles between the cases and controls were
evaluated by calculating OR. Using the v2 test, we
assessed whether the distribution of GGN repeats
varied by the level of CAG repeats and also deter-
mined the linkage disequilibrium between the repeats
separately among the cases and controls. To further
test whether GGN microsatellite contributes to the risk
in combination with CAG microsatellite, logistic
regression analysis was carried out with CAG and
GGN as binary covariates.
Mean GGN repeat in different groups of Gleason
score, age and PSA were compared by t test. GGN
repeat distributions within each prognostic factor (age,
grade and PSA values) were also calculated. One-way
analysis of variance (ANOVA) was used to compare
more than two mean values. All the tests were two-
sided and the level of significance is taken as 5%. All
the statistical analysis of data were performed using the
statistical software SPSS (version 13).
Results
The mean age of prostate cancer patients, BPH and
healthy controls were 67.5, 65.5 and 66.5 years,
respectively. Mean serum PSA level measured at the
time of diagnosis was 44.4 ng/ml in prostate cancer
patients. The PSA values were in the normal range
(£4 ng/ml) in both the BPH patients and the healthy
controls. Selected characteristics of prostate cancer
cases and controls are presented in Table 1.
The number of GGN repeats among cases and
healthy controls ranged from 15 to 26 with a mean of
21, whereas in BPH the number of GGN repeat was
between 15–23 with mean of 21. Thus, no significant
difference was seen in the mean GGN repeat among
the cases and controls; also, within the control group
the mean GGN repeats length was 21 in both BPH
and healthy controls. The patient and control allelic













Mean ± SD 67.5 ± 8.8 66.5 ± 6.7 65.5 ± 6.6
Range 44.0–98.0 50.0–81.0 55.0–77.0
PSA (ng/ml)
Mean ± SD 44.4 ± 31.5 – –
Gleason score
2 3.4% – –
3 8.0% – –
4 21.8% – –
5 12.6% – –
6 9.2% – –
7 24.1% – –
8 14.9% – –
9 4.6% – –
10 1.4% – –
CAG repeats
Mean ± SD 17.0 ± 3.3 20.7 ± 3.9 21.3 ± 3.3
Median 17 21 21
Range 9–25 11–29 13–25
GGN repeats
Mean ± SD 21.2 ± 1.8 21.03 ± 2.1 21.18 ± 1.6
Median 21.45 21.3 21.42
Range 15–26 15–26 15–23
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distributions for the (GGN) n polymorphism are
shown in Fig. 1.
For the polyglycine tract (GGT) 3(GGG) 1(GGT)
2(GGC) n, there was no variation in the number of
GGT and GGG trinucleotides in all the samples ana-
lyzed, although the number of GGC repeats was highly
variable. The pattern was always three GGT, one
GGG, and two GGT, followed by a variable number of
GGC repeats. Hence a 22 GGN repeat refers to 6 re-
peats corresponding to the consensus sequence and 16
GGC repeats. In the (GGN) n system, the 2 alleles, 21
and 22 repeats were predominant and together they
accounted for 78% in patients and 75% in control
populations of all 12 alleles genotyped.
In order to assess the risk associated with GGN re-
peats, the study subjects were dichotomized based on
the mean GGN repeat. Men with GGN repeats £21
had no significant risk of prostate cancer compared to
those with >21 repeats (OR 0.91 at 95% CI = 0.52–
1.58) (Table 2).
The CAG repeat polymorphism analyzed in our
previous study revealed a significant difference in the
mean CAG repeats between prostate cancer patients
and controls (17.0 vs. 20.7; P < 0.001) and, men with
CAG repeat length £19 had a significantly increased
risk for cancer than those with >19 CAG repeats (OR-
5.90 at 95% CI 3.2–11.2; P < 0.001) (Krishnaswamy
et al. 2006). In order to determine whether specific
combination of CAG and GGN alleles differed sig-
nificantly between cases and controls, we combined the
CAG repeat data with the GGN repeats, observed in
the present study. There was prevalence of CAG £19/
GGN £21 and CAG £19/GGN >21 haplotypes in cases
compared to controls. Thus, men with CAG £19/GGN
£21 (OR-5.2 at 95% CI-2.17–12.48, P < 0.001) and
CAG £19/GGN >21(OR-6.9 at 95% CI–2.85–17.01,
P < 0.001) had an increased risk compared to men with
CAG >19/GGN >21 whereas individuals with CAG
>19 and GGN£21 were not at an increased risk for
cancer (OR-1.1; 95% CI-0.14–2.83) (Table 3). Logistic
regression analysis with CAG and GGN as binary co-
variates also showed a significant association
(P < 0.001).
We further tested a possible association (linkage)
between CAG and GGN microsatellites separately
among the cases and controls by cross-classifying them
into groups based on mean GGN (£21 and >21) and
mean CAG (£19 and >19) repeat lengths (Table 4).
However, we did not observe a significant linkage be-
tween the two microsatellites among the cases as well
as among the controls.
We also analyzed GGN repeat polymorphism of the
prostate cancer patients by categorizing them into dif-
ferent groups based on age, Gleason score and PSA
levels (Table 5). With respect to tumor grade, patients
with well and moderately differentiated tumor were
classified as low grade (GS < 7) and those with poorly
differentiated tumor as high grade (GS ‡ 7). Although a
trend towards short mean GGN repeat length with high
grade was observed, it was non-significant (P–0.09).
With respect to age at diagnosis, subjects were
stratified into four groups based on quartiles (£62, 63–
66, 67–72, >72), and into two groups with regard to
PSA levels, with mean PSA value as the cut-off. The
mean GGN repeat within each of the age groups and
PSA groups revealed no significant difference. More-
over, stratified analysis of GGN repeats distribution
based on the age of onset, tumor grade and PSA levels
revealed no significant association with any of the
variables (Table 5).
Discussion
Studies on the association of AR-GGN repeat length




























Fig. 1 Distribution of GGN repeats in Androgen receptor gene
among prostate cancer patients and controls
Table 2 Risk of prostate cancer in relation to the number of






(n = 86) (%)
Controls
(n = 119) (%)
OR 95% CI P
>21 44 (51) 58 (49) 1.0
£21 42 (49) 61 (51) 0.91 0.52–1.58 NS
OR Odds ratio, CI confidence interval, NS non significant
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results. Our study reveals that singly the GGN repeats
are not associated with prostate cancer risk, but when
combined with CAG repeats, men with CAG £19/
GGN £21 and CAG £19/GGN >21 have an increased
risk compared to men with CAG >19/GGN >21.
However, we did not observe any statistically signifi-
cant association between GGN repeats length and age
of diagnosis, Gleason score and PSA levels.
The distribution of GGN microsatellites has been
reported to differ significantly among different ethnic
groups. High-risk African–Americans were found to
possess the lowest frequency (20%) for GGN allele,
with 22 repeats; whereas the comparable values for
intermediate-risk whites and low-risk Asians were 57
and 70%, respectively (Irvine et al. 1995). Among the
Western (Platz et al. 1998, Chen et al. 2002) as well as
Chinese men (Hsing et al. 2000) GGN repeat length of
23 was predominant. Hence, they suggested that 23
GGN repeats might represent the coding sequence for
optimal AR protein conformation and activity. How-
ever, in our study only 1.7% of the subjects had 23
GGN repeats and the repeats clustered around 22;
where, 42% of the subjects had 22 repeats and 33%
had 21 repeats, thus revealing the polymorphic nature
Table 3 Risk of prostate cancer in relation to the combined distribution of number of CAG and GGN repeats in exon 1 of AR gene
Repeats Patients (%) Controls (%) OR 95% CI P
CAG > 19/GGN > 21 10 (11.6) 39 (32.7) 1.0
CAG £ 19/GGN £ 21 32 (37) 24 (20) 5.2 2.17–12.48 <0.001
CAG £ 19/GGN > 21 34 (39.5) 19 (15) 6.9 2.85–17.01 <0.001
CAG > 19/GGN £ 21 10 (11.6) 37 (31) 1.1 0.14–2.83 NS
OR Odds ratio, CI confidence interval, NS non significant
Table 4 Frequency distribution of AR gene CAG and GGN repeat lengths among prostate cancer cases and controls
Group No. of GGN repeats No. of CAG repeats Total (%)
£19 (%) >19 (%)
Casesa (n = 86) £21 32 (48.5) 10 (50) 42 (48.8)
>21 34 (51.5) 10 (50) 44 (51.2)
Total 66 (100) 20 (100) 86 (100)
Controlsb (n = 119) £21 24 (55.8) 37 (48.7) 61 (51.3)
>21 19 (44.2) 39 (51.3) 58 (48.7)
Total 43 (100) 76 (100) 119 (100)
a v2 test of independence: two sided P = 0.905
b v2 test of independence: two sided P = 0.455





P value Distribution of GGN repeats within each
prognostic factor
P value
No. of cases with £21
GGN repeats (%)
No. of cases with >21
GGN repeats (%)
Grade
GS < 7 (Low grade) 47 21.53 ± 1.63 0.09 21 (44.7) 26 (55.3) NS
GS ‡ 7 (High grade) 39 20.85 ± 2.11 21 (53.8) 18 (46.2)
Age
£62 22 21.14 ± 1.86 NS 14 (64) 8 (36) NS
63–66 24 21.17 ± 2.09 11 (46) 13 (54)
67–72 24 21.04 ± 1.37 11 (46 13 (54)
>72 16 21.69 ± 2.30 6 (37) 10 (63)
PSA level
£48 53 21.15 ± 2.30 0.665 26 (49.1) 27 (50.9) NS
>48 33 21.33 ± 0.89 16 (48.5) 17 (51.5)
GS Gleason score, PSA prostate specific antigen, NS non significant, SD standard deviation
1002 J Hum Genet (2006) 51:998–1005
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and distinct ethnic variation in GGN repeat tract
length.
Similar to our results, no significant genotype-spe-
cific prostate cancer risk was found with GGN repeat
polymorphism among Caucasians in Britain (Edwards
et al. 1999), French–German men (Correa-Cerro et al.
1999) and Caucasians in America (Chen et al. 2002).
Moreover, men with short GGN repeats were not at
increased risk in familial prostate cancer cases (Miller
et al. 2001; Cicek et al. 2004). In addition, a recent
study on early onset prostate cancer in British men also
reported lack of association between GGN repeats and
prostate cancer risk (Forrest et al. 2005).
In contrast to our results, men with GGC repeats
£16 have been reported to exhibit higher risk estimates
than men with >16 repeats (Stanford et al. 1997).
Moreover, a significantly increased frequency of the
GGC repeat £16 has been reported in hereditary as
well as sporadic prostate cancer in a study predominant
of Caucasians (Chang et al. 2002). In addition, among
Chinese men those with <23 GGN repeats had 12%
increased risk of prostate cancer compared to those
with ‡23 GGN repeats (Hsing et al. 2000). Thus, our
results on GGN repeats correlate with and deviate
from some of the previous studies revealing the ethnic
differences in AR GGN polymorphism and association
with prostate cancer (Table 6).
When we combined both the CAG and GGN re-
peats, we observed men with the haplotypes
CAG £ 19/GGN £ 21 and CAG £ 19/GGN > 21 to
exhibit increased risk compared to men with
CAG > 19/GGN > 21 haplotype. Table 7 reveals the
combined distribution of the repeats observed in dif-
ferent studies. Our results are thus consistent with
earlier studies, where the subgroups with two short
repeats (CAG < 22; GGC £ 16) had a twofold in-
creased risk relative to those with long repeats
(CAG ‡ 22; GGC > 16) (Stanford et al. 1997). Platz
et al. (1998) reported an increased risk for those with a
GGN = 23 and CAG < 21 compared to a GGN other
than 23 and a CAG > 23. In contrast, men with
CAG < 22 and GGN £ 23 repeats were not at in-
creased risk of prostate cancer (Chen et al. 2002).
Since the AR gene is located on the X-chromosome,
the two microsatellites, which are in close proximity at
this locus, can be associated with each other or in other
words one would expect to find linkage disequilibrium
between them. Irvine et al. (1995) have observed sig-
nificant linkage disequilibrium between the CAG and
GGN repeats only among cases and not among con-
trols. However, Platz et al. (1998) reported linkage
disequilibrium among cases and controls. In contrast,
our results revealed no significant linkage between the
repeats among cases as well as controls. The absence of
linkage between the repeats might indicate that either
one or both the repeats mutate at a relatively high rate
and independent of each other.
Studies on the association of GGN repeats and the
age of diagnosis have revealed contrasting findings.
Stanford et al. (1997) observed men with GGC £ 16 to
be at increased risk regardless of the age at diagnosis.
But Miller et al. (2001) reported a reduced risk among
men diagnosed at the age £ 66 years and an increased
risk among men diagnosed at the age ‡ 66 years.
Moreover, a reduced risk was observed with £17 re-
peats in men aged 70 years or older and no evidence of
any association in men <70 years (Chen et al. 2002).
However, our study did not find any association be-
tween age and the prostate cancer risk.
Although a trend of short mean GGN repeat length
with high grade was observed in our study the associ-
ation was not significant. Hakimi et al. (1997) have
reported short GGN repeats to identify a sub-popula-
tion of patients with clinically localized disease. How-
ever, Edwards et al. (1999) have observed long GGN
alleles at higher frequency in advanced stages and
Table 6 Studies on AR-GGN repeat polymorphism and prostate cancer risk
Study Study population Results
GGN repeats OR (%CI)
Present study* Asians/ South Indians £21vs. >21 0.91 (0.52–1.58)
Irvine et al. 1995 Non Hispanic whites Others vs. 16 1.18 (data not available)
Stanford et al. 1997 Caucasians/United States £16 vs. >16 1.60 (1.07–2.41)
Platz et al. 1998 Physicians’ Health Study/USA 23 vs. not 23 1.2 (0.97–1.49)
Edwards et al. 1999 Caucasians/United Kingdom £16 vs. >16 1.06 (0.57–1.96)
Hsing et al. 2000 Asian/China <23 vs. ‡23 1.12 (0.71–1.78)
Miller et al. 2001 Caucasians £16 vs. >16 0.98 (0.46–2.06)
Chu chen et al. 2002 Caucasians/America £17 vs. >17 0.8 (0.57–1.12)
Chang et al. 2002 Caucasians/United States £16 vs. ‡17 1.51 (0.99–2.32)
Cicek et al. 2004 Caucasians and African Americans/United States £16 vs. >16 1.04 (0.71–1.52)
Forrest et al. 2005 British men/United Kingdom £16 vs. >16 1.06 (0.78–1.44)
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grades. They also reported long GGN alleles to be
associated with shorter time to relapse and worse
overall survival. Thus we propose that assessing the
role of CAG and GGN repeats with relapse and
overall survival of the patients will enable prediction of
the growth behavior of early-stage tumors and thus
validate the prognostic significance of the repeats in
prostate cancer.
Since the AR transactivation results in PSA
secretion, we assessed the association of PSA levels
with AR GGN genotype but did not observe any
significant association. As the GGN repeats are in the
transactivation domain, it is possible that a single–
amino acid difference disrupts the binding affinity of
the domain enough to up- or down-regulate the for-
mation of a critical regulatory complex. However, the
two functional studies reported so far are contradic-
tory, with one revealing no substantial effect of the
deletion of GGN repeats on AR activity (Jenster
et al. 1994), whereas another reported diminished
AR activity (Gao et al.1996). Thus the functional
significance of the GGN repeats needs to be further
evaluated.
The differences in the results reported for each
study population may be partially explained by the
gene–environment interaction. Differences in the study
design and reference CAG and GGN lengths may also
contribute to the divergent results in the epidemio-
logical studies. It has also been proposed that the
polymorphic CAG and GGN repeats function as low
penetrance prostate cancer alleles that may require
additional genetic or environmental factors to result in
increased cancer risk (Nwosu et al. 2001). Moreover,
they might be in linkage disequilibrium with other
disease causing mutations in the AR gene or with other
unknown adjacent genes that affect prostate cancer
risk. Although numbers of repeats have a quantitative
feature, frequency of 21 and 22 GGN repeats is very
high and others are almost negligible. Therefore the
positive association could be due to difference between
the allele with 21 repeats and the allele with 22 repeats,
rather than due to quantitative effect of number of
repeats.
To the best of our knowledge, this is the first study
to investigate the association between GGN repeat
polymorphism and the relative risk of prostate cancer
in Indian men. Our results suggest that specific hapl-
otypes of AR attribute to risk of prostate cancer. Be-
cause of the significance of AR in prostate cancer,
investigation of factors that interact with the polyglu-
tamine and polyglycine region of the AR gene to alter
AR function and modulate prostate cancer risk is an
important area for future research.
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Table 7 Studies on combined
distribution of AR-CAG and
GGN repeat polymorphism in
prostate cancer
Study Population Results
CAG and GGN/GGC OR (%CI)
Present study Asians/ South Indians £19, £21 vs. >19, >21 5.2 (2.17–12.48)
£19, >21 vs. >19, >21 6.9 (2.85–17.01)
>19, £21 vs. >19, >21 1.1 (0.139–2.83)
Irvine et al. 1995 Non Hispanic whites <22, not 16 vs. ‡22, 16 2.1 (NA)
Stanford et al. 1997 Caucasians/ United States ‡22, £16 vs. ‡22, >16 1.15 (0.56–2.35)
<22, >16 vs. ‡22, >16 1.54 (0.83–2.86)
<22, £16 vs. ‡22, >16 2.05 (1.09–3.84)
Platz et al. 1998 Physicians’
Health Study /USA
>23,23 vs. >23 not 23 1.17 (0.77–1.77)
21–23, not 23 vs.>23 not 23 1.39 (0.93–2.06)
21–23,23 vs. >23 not 23 1.22 (0.82–1.83)
<21, not 23 vs.>23 not 23 1.49 (1.02–2.15)
<21,23 vs. >23 not 23 1.62 (1.07–2.44)
Hsing et al. 2000 Asian/China ‡23, <23 vs. ‡23, ‡23 1.48 (0.76–2.88)
<23, ‡23 vs. ‡ 23, ‡23 1.85 (1.21–2.82)
<23, <23 vs. ‡23, ‡23 1.75 (0.9–3.41)
Miller et al. 2001 Caucasians ‡22, £16 vs. ‡22, >16 0.63 (0.18–2.2)
<22, >16 vs. ‡22, >16 0.69 (0.17–2.74)
<22, £16 vs. ‡22, >16 1.06 (0.25–4.46)
Chu chen et al. 2002 Caucasians/ America ‡22, £17 vs. ‡22, >17 0.54 (0.32–0.91)
<22, >17 vs. ‡22, >17 0.55 (0.31–0.98)
<22, £17 vs. ‡22, >17 0.56 (0.32–0.98)
Chang et al. 2002 Caucasians/ United States ‡22, £16 vs. ‡22, ‡17 1.27 (0.68–2.39
£21, ‡17vs. ‡22, ‡17 0.65 (0.32–1.30)
£21, £16 vs. ‡22, ‡17 1.14 (0.62–2.12)
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